Takeda Pharmaceutical Ownership
| TKD Stock | EUR 25.17 0.05 0.20% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Takeda |
Takeda Stock Ownership Analysis
About 41.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.95. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Takeda Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.58. The entity last dividend was issued on the 30th of March 2023. Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 49578 people. To find out more about Takeda Pharmaceutical contact Christophe Weber at 81 3 3278 2111 or learn more at https://www.takeda.com.Takeda Pharmaceutical Outstanding Bonds
Takeda Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Takeda Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Takeda bonds can be classified according to their maturity, which is the date when Takeda Pharmaceutical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Currently Active Assets on Macroaxis
Other Information on Investing in Takeda Stock
Takeda Pharmaceutical financial ratios help investors to determine whether Takeda Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Takeda with respect to the benefits of owning Takeda Pharmaceutical security.